It is the first and only treatment that has been approved for geographic atrophy, a leading cause of blindness, according to a Feb. 17 news release.
Syfovre is set to be available to specialty distributors and pharmacies across the country in March.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
